RNA specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) has revealed encouraging topline results from its Phase III HELIOS-B study.
The company is testing vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive and potentially fatal disease caused by the buildup of abnormal proteins in the heart.
The therapy is already approved and marketed as Amvuttra for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze